KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $1.58 $2.30 Friday, 26th Apr 2024 CTMX stock ended at $1.59. This is 0.625% less than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 3.77% from a day low at $1.59 to a day high of $1.65.
90 days $1.38 $2.86
52 weeks $1.04 $2.86

Historical CytomX Therapeutics prices

Date Open High Low Close Volume
Apr 12, 2016 $13.43 $13.49 $13.01 $13.15 34 763
Apr 11, 2016 $13.62 $13.65 $13.13 $13.36 21 064
Apr 08, 2016 $13.58 $13.66 $13.29 $13.58 27 422
Apr 07, 2016 $13.05 $13.65 $13.00 $13.30 276 178
Apr 06, 2016 $13.20 $13.58 $12.90 $13.20 88 575
Apr 05, 2016 $13.23 $13.44 $12.68 $13.22 91 991
Apr 04, 2016 $13.33 $13.75 $13.07 $13.60 55 893
Apr 01, 2016 $12.67 $13.49 $12.69 $13.35 60 448
Mar 31, 2016 $12.72 $13.07 $12.66 $12.90 61 580
Mar 30, 2016 $12.70 $12.94 $12.59 $12.69 22 214
Mar 29, 2016 $12.28 $12.91 $12.28 $12.62 34 600
Mar 28, 2016 $12.87 $13.40 $12.18 $12.51 46 100
Mar 24, 2016 $12.66 $13.04 $12.50 $12.75 79 600
Mar 23, 2016 $12.85 $13.43 $12.24 $12.36 63 800
Mar 22, 2016 $12.70 $13.11 $12.35 $12.80 79 400
Mar 21, 2016 $12.33 $12.98 $12.33 $12.70 88 600
Mar 18, 2016 $12.05 $12.80 $11.81 $12.44 74 300
Mar 17, 2016 $12.68 $12.68 $11.18 $11.94 89 400
Mar 16, 2016 $13.00 $13.10 $12.66 $12.87 27 800
Mar 15, 2016 $12.89 $13.40 $12.45 $12.89 45 800
Mar 14, 2016 $12.93 $13.62 $12.68 $12.84 53 600
Mar 11, 2016 $13.01 $14.05 $12.30 $13.17 63 400
Mar 10, 2016 $12.89 $13.20 $12.23 $12.49 35 100
Mar 09, 2016 $13.09 $13.18 $12.51 $12.67 27 900
Mar 08, 2016 $13.41 $13.41 $12.69 $12.82 68 700
Click to get the best stock tips daily for free!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT